Entry into the Pharmacy Business
First written in FY2023-Q1. 2 of 4 entries say "Worsened", first in FY2024-Q2. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025MitigatedAnnual report
「Sales from the Other business were ¥95,203 thousand, a decrease of ¥35,949 thousand year on year, while segment profit was ¥589 thousand, compared with a loss of ¥11,617 thousand in the previous fiscal year.」
Other businesses, including the dispensing pharmacy business, turned from a segment loss in the previous fiscal year to a profit of ¥589 thousand in the current fiscal year. This shows current-period results after the goodwill impairment disclosed in the previous fiscal year. - FY2024WorsenedAnnual report
「For the fixed assets owned by each business site, the Company assessed whether to recognize impairment losses because, during the current fiscal year, the equipment leasing, food and beverage, and pharmacy businesses had been performing below their initially formulated business plans, with operating income or cash flow remaining negative on a continuing basis, indicating signs of impairment.」
The dispensing pharmacy business and other operations fell below the initial plan, and operating income/loss or cash flow remained negative, so impairment indicators and the difficulty of recovering the investment have been disclosed. An impairment loss of ¥112.702 million was recognized for the pharmacy business. - FY2024-Q2WorsenedAnnual report
「Following a review of future business plans for the dispensing pharmacy and food and beverage businesses, the Company determined that the excess earning power initially anticipated could no longer be expected. Accordingly, it reduced the carrying amount of goodwill to its recoverable amount and recognized the resulting decrease as an impairment loss under extraordinary losses.」
For the dispensing pharmacy and food and beverage businesses, the Company determined that the excess earning power initially anticipated could no longer be expected following a review of the business plans and impaired the goodwill. - FY2023-Q1First statedAnnual report
「As part of future business diversification and to establish a foothold for entering the dispensing-pharmacy business: business acquisition date, 1 November 2022; cash consideration, ¥170.000 million; acquisition cost, ¥170.000 million; goodwill, ¥130.000 million; amortization method and period, straight-line amortization over 5 years.」
The Company acquired the dispensing-pharmacy business of おゆみ薬局 for ¥170.000 million in cash on 1 November 2022, establishing a foothold in the business. The goodwill of ¥130.000 million will be amortized on a straight-line basis over 5 years.